Download PDF
Thromb Haemost 1964; 11(02): 485-496
DOI: 10.1055/s-0038-1654844
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Hypercoagulability Syndrome Due to Heparin Co-Factor Deficiency

A Case Report and Review of the Literature
B. J Koszewski
1   Hematology Research Laboratory, Creighton Memorial-St. Joseph’s Hospital and the Creighton University School of Medicine, Omaha, Nebraska, U.S.A
,
H Vahabzadeh
1   Hematology Research Laboratory, Creighton Memorial-St. Joseph’s Hospital and the Creighton University School of Medicine, Omaha, Nebraska, U.S.A
› Author Affiliations
Further Information

Publication History

Publication Date:
22 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

A case of hypercoagulability syndrome in a 35 years old male is reported. An abnormal heparin resistance was found which could be defined by means of a heparin clot-inhibition test as a deficiency in heparin co-factor. The required anticoagulant doses of heparin were forty times as high as in cases with intact heparin co-factor. The factor seemed to be used up in the process of coagulation, as plasma, but not serum, was able to correct the deficiency in vitro. Plasma infusions were helpful for four days, but a complete recovery was achieved only after an intensive course of fever therapy.

The phenomenon of blood clotting should be regarded as a dynamic process which is facilitated by an array of clot promoting factors and opposed by a system of natural anticoagulants.

 

  • References

  • 1 Alexander B. Blood coagulation and thrombotic disease. Circulation 25: 872 1962;
    CrossrefPubMedGoogle Scholar
  • 2 Sise H. S, Moschos C. S, Becker R. On the nature of hypercoagulability. Amer. J. Med. 33: 667 1962;
    CrossrefPubMedGoogle Scholar
  • 3 Crafoord C. Preliminary report on postoperative treatment with heparin as a preventative of thrombosis. Acta chir. scand. 79: 407 1937;
    PubMedGoogle Scholar
  • 4 de TaJcats G. Heparin tolerance. A test of the clotting mechanism. Surg. Gynec. Obstet. 77: 31 1943;
    PubMedGoogle Scholar
  • 5 Koller F. Über die klinische Bedeutung der Blutgerinnungsstörungen. Schweiz, med. Wschr. 75: 290 1945;
    PubMedGoogle Scholar
  • 6 Soulier J. P, Bolloch A. G. The in vitro heparin tolerance test in the control of dicumarol therapy. Actamed. scand. 140: 132 1951;
    PubMedGoogle Scholar
  • 7 Quick A. J. On the coagulation defect in peptone shock. Amer. J. Physiol. 116: 535 1936;
    PubMedGoogle Scholar
  • 8 Gormsen J. A technique for the heparin tolerance test. Brit. J. Haemat. 05: 257 1959;
    CrossrefPubMedGoogle Scholar
  • 9 Holger-Madsen T. The plasma heparin time. Acta haemat. 21: 301 1959;
    CrossrefPubMedGoogle Scholar
  • 10 Jaques L. B, Keeri-Szanto E. Heparinase. Distribution of enzyme in various tissues and its action on natural heparins and certain synthetic anticoagulants. Canad. J. med. Sci. 30: 353 1952;
    PubMedGoogle Scholar
  • 11 Godai H. C. Heparin tolerance and the plasma proteins. Scand. J. clin. Lab. Invest. 13: 314 1961;
    CrossrefPubMedGoogle Scholar
  • 12 Hjort P. F, Hasselback R. A critical review of the evidence for a continuous hemostasis in vivo. Thrombos. Diathes. haemorrh. (Stuttg.) 06: 580 1961;
    PubMedGoogle Scholar
  • 13 Warren R. Postoperative thrombophilia. New Engl. J. Med. 249: 95 1953;
    PubMedGoogle Scholar
  • 14 Schupbach A, Herrmann E. Thrombosekrankheit bei essentieller Thrombocythemie. Schweiz, med. Wschr. 84: 95 1954;
    PubMedGoogle Scholar
  • 15 Wright H. P. Changes in adhesiveness of blood platelets following parturition and surgical operations. J. Path. Bact. 54: 461 1942;
    CrossrefPubMedGoogle Scholar
  • 16 McDonald L, Edgill M. Coagulability of the blood in ischemic heart disease. Lancet. II: 457 1957;
    PubMedGoogle Scholar
  • 17 Murphy E. A, Mustard J. F. Coagulation tests and platelet economy in atherosclerotic and control subjects. Circulation. 25: 114 1962;
    CrossrefPubMedGoogle Scholar
  • 18 Wessler S. Thrombosis in the presence of vascular stasis. Amer. J. Med. 23: 648 1962;
    PubMedGoogle Scholar
  • 19 Spittel J. A, Pascuzzi C. A, Thompson J. H, Owen C. A. Acceleration of early stages of coagulation in certain patients with occlusive arterial or venous diseases : Use of a modified thromboplastin generation test to evaluate clot acceleration. Proc. Mayo Clin. 35: 37 1960;
    PubMedGoogle Scholar
  • 20 Pascuzzi C. A, Spittel J. A, Thompson J. H, Owen G. A. Thromboplastin generation accelerator, a newly recognized component of the blood coagulation mechanism present in excess in certain thrombotic states. J. clin. Invest. 40: 1006 1961;
    CrossrefPubMedGoogle Scholar
  • 21 Gormsen J. Thrombelastography and hypercoagulability. Acta med. scand. 170: 313 1961;
    PubMedGoogle Scholar
  • 22 Egeberg O. Clotting factor levels in patients with coronary atherosclerosis. Scand. J. clin. Lab. Invest. 14: 253 1962;
    CrossrefPubMedGoogle Scholar
  • 23 Loeliger E. A, Esch B, Romey-Wachter CChHaar, Booij H. L. Factor VII, its turnover rate and its possible role in thrombogenesis. Thrombos. Diathes. haemorrh. (Stuttg.) 04: 196 1960;
    PubMedGoogle Scholar
  • 24 de Nicola P. Factor VII (SPCA), its physiopathologic significance. Blood. 07: 947 1953;
    PubMedGoogle Scholar
  • 25 Alexander B, Myers L, Kenny J, Goldstein R, Gutewich V, Grinspoon L. Blood coagulation in pregnancy: Proconvertin and prothrombin, and the hypercoagulable state. New Engl. J. Med. 254: 358 1956;
    CrossrefPubMedGoogle Scholar
  • 26 Cooperberg A. A, Teitelbaum J. I. The concentration of antihemophilic globulin (AHG) inpatients with coronary artery disease. Ann. intern. Med. 54: 899 1961;
    CrossrefPubMedGoogle Scholar
  • 27 McLean J. The thromboplastic action of cephalin. Amer. J. Physiol. 41: 250 1916;
    PubMedGoogle Scholar
  • 28 Waugh T. R, Ruddick D. W. Test for increased coagulability of blood. Canad. med. Ass. J. 50: 547 1944;
    PubMedGoogle Scholar
  • 29 Howell W. H. The purification of heparin and its chemical and physiological reactions. Bull. Johns Hopk. Hosp. 42: 199 1928;
    PubMedGoogle Scholar
  • 30 Mellanby J. Heparin and blood coagulation. Proc. roy Soc. Med. 116: 1 1935;
    PubMedGoogle Scholar
  • 31 Quick A. J. The normal antithrombin of the blood and its relation to heparin. Amer. J. Physiol. 123: 712 1938;
    PubMedGoogle Scholar
  • 32 Brinkhous K. M, Smith H. P, Warner E. D, Seegers W. H. The inhibition of blood clotting: An unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. Amer. J. Physiol. 125: 683 1939;
    PubMedGoogle Scholar
  • 33 Usteri C. Das Heparinkomplement und seine physiologisch-klinische Bedeutung. Inaug. Diss., Zürich. 1949
    PubMedGoogle Scholar
  • 34 Snellman O, Sylven B, Julen G. Analysis of the native-lipoprotein complex including the identification of a heparin complement (heparin co-factor) obtained from extracts of tissue mast cells. Biochem. biophys. Acta. 07: 98 1951;
    CrossrefPubMedGoogle Scholar
  • 35 Lyttleton J. W. The antithrombic activity of heparin. Biochem. J. 58: 15 1954;
    CrossrefPubMedGoogle Scholar
  • 36 Astrup T, Darling S. Antithrombin and heparin. Acta physiol, scand. 05: 13 1943;
    CrossrefPubMedGoogle Scholar
  • 37 Monkhouse F. C, France E. S, Seegers W. H. Studies on the antithrombin and heparin co-factor activities of a fraction adsorbed from plasma by aluminum hydroxyde. Circulât. Res. 03: 397 1955;
    PubMedGoogle Scholar
  • 38 Monkhouse F. C, Milojevic S. The separation of antithrombin and heparin-co-factor from plasma albumin. Thrombos. Diathes. haemorrh. (Stuttg.) 09: 221 1963;
    PubMedGoogle Scholar
  • 39 Howell W. H. Theories of blood coagulation. Physiol. Rev. 15: 435 1935;
    CrossrefPubMedGoogle Scholar
  • 40 Loeliger A. Natural anticoagulants. Ned. T. Geneesk. 105: 1485 1961;
    PubMedGoogle Scholar
  • 41 Kudrjashov B. A. On the physiological anticoagulanting system. Thrombos. Diathes. haemorrh. (Stuttg.) 06: 371 1961;
    PubMedGoogle Scholar
  • 42 Rosenthal R. L. Property of plasma thromboplastin antecedent (PTA) in relation to blood coagulation. J. Lab. clin. Med. 45: 128 1955;
    PubMedGoogle Scholar
  • 43 Berry E. G. The degeneration of brain thromboplastin in the presence of normal serum. J. clin. Path. 20: 342 1957;
    PubMedGoogle Scholar
  • 44 Scott T. G, Symons C, Markham R. L. Antithromboplastin in human serum and plasma. Nature (Lond.) 186: 248 1960;
    CrossrefPubMedGoogle Scholar
  • 45 Tocantis L. M. Demonstration of antithromboplastin activity in normal and hemophilic plasmas. Amer. J. Physiol. 139: 265 1942;
    PubMedGoogle Scholar
  • 46 Schneider C. L. The active principle of placental toxin: Thromboplastin, its inactivator in blood antithromboplastin. Amer. J. Physiol. 149: 123 1947;
    PubMedGoogle Scholar
  • 47 Israels L. G, Foerster J, Zipursky A. Anaturally occuring inhibitor of the first stage of blood coagulation. Brit. J. Haemat. 06: 275 1960;
    CrossrefPubMedGoogle Scholar
  • 48 Seegers W. H, Miller K. D, Andrews E. B, Murphy R. C. Fundamental interaction and effect of storage, ether adsorbants, and blood clotting on plasma antithrombin activity. Amer. J. Physiol. 169: 700 1952;
    PubMedGoogle Scholar
  • 49 Foa C. Sulle leggi d’azione della trombina. Arch. Fisiol. 10: 479 1912;
    PubMedGoogle Scholar
  • 50 Seegers W. H. Multiple protein interactions as exhibited by the blood clotting mechanism. J. phys. Colloid. Chem. 51: 198 1947;
    PubMedGoogle Scholar
  • 51 Quick A. J, Favre-Gilly J. Fibrin, a factor influencing consumption of prothrombin in coagulation. Amer. J. Physiol. 158: 387 1949;
    PubMedGoogle Scholar
  • 52 Copley A. L, Becher B. Human, cow and rabbit native fibrin powders al anticoagulants. Nature. 192: 568 1961;
    CrossrefPubMedGoogle Scholar